Compare Novo Nordisk A/S (NVO) vs abrdn Physical Palladium Shares ETF (PALL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs abrdn Physical Palladium Shares ETF — how do they compare? Novo Nordisk A/S trades at $46.46 (market cap $207.85B), while abrdn Physical Palladium Shares ETF trades at $24.71. The key difference: Novo Nordisk A/S pays a 3.81% dividend while abrdn Physical Palladium Shares ETF pays none, and Novo Nordisk A/S is trading nearer its 52-week high, abrdn Physical Palladium Shares ETF nearer its low. Which is the better fit depends on your goals.
| NVO | PALL | |
|---|---|---|
Market Cap | $207.85B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $63.98 | $37.18 |
52-Week Low | $35.29 | $19.96 |
Enterprise Value | $222.55B | — |
Dividend Yield | 3.81% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $46.465, down 2.65% today, with a neutral technical signal. The stock shows strong fundamentals, including a P/E of 11.62, net income margin of 35.35%, and consistent earnings beats in recent quarters. Recent news highlights competitive pressures from Eli Lilly and mixed investor reactions to Q2 2026 results, despite an upwardly revised full-year outlook.
Outlook remains positive due to robust GLP-1 drug demand and profitability, but risks include pricing pressure and competition. Analysts are predominantly bullish (57.9% buy ratings), supporting a favorable long-term view despite near-term volatility.
PALL trades at $24.85, down 1.04% over 24 hours. Technical indicators show a bullish trend with moving averages supporting a buy signal, though the RSI suggests potential overbought conditions. The stock underwent a 1:5 split effective May 18, 2026. Recent financial ratios are unavailable, limiting fundamental assessment. News sentiment highlights palladium's price weakness as a potential buying opportunity amid supply risks and industrial demand.
Outlook: PALL presents a speculative opportunity tied to palladium's recovery, with technical strength but limited fundamental data. Risks include commodity price volatility and macroeconomic factors. Investors should weigh the bullish technicals against the absence of current financial metrics and exposure to precious metal market fluctuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About abrdn Physical Palladium Shares ETF
PALL is a physically-backed ETF that tracks the spot price of palladium. It holds physical bullion in secure vaults, offering a liquid way to invest in this precious metal primarily used in automotive catalytic converters and electronics.
Read more on PALL →
